As the molecular pathogenesis of ECD disease has been explored, many therapeutic options, including interferon-α (IFN-α), BRAF, MEK targeted therapy, and anti-cytokine biotherapy, have been widely used to treat ECD. The gene discussed is BRAF; the disease is familial atrioventricular septal defect.